Search research articles
Contact Us
Filters
Showing results (411-420 of 1,289) with videos related to
Page
of 129
Sort By:
Leukemia
|
May 21, 2016
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes
F Cervantes-Gomez, V Kumar Patel, P Bose, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)
|
January 1, 1990
The effects of swabbing the skin on apparent blood ethanol concentration
G J Peek, A Marsh, J Keating, et al.
Leukemia & Lymphoma
|
June 20, 2015
Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells
Fabiola Cervantes-Gomez, Bethany Lavergne, Michael J Keating, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
March 1, 2007
Somatostatin decreases voltage-gated Ca2+ currents in GH3 cells through activation of somatostatin receptor 2
Seung-Kwon Yang, Helena C Parkington, Jacques Epelbaum, et al.
Journal of Biomedical Materials Research
|
January 15, 2000
Mechanical environment affects allograft incorporation
J Benevenia, M Zimmerman, J Keating, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 1995
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia
V Gandhi, E Estey, M Du, et al.
Endocrine
|
January 3, 2006
Ghrelin reduces voltage-gated potassium currents in GH3 cells via cyclic GMP pathways
Xue Feng Han, Yun Long Zhu, Maria Hernandez, et al.
Leukemia Research
|
August 4, 2009
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years
Stefan Faderl, William Wierda, Susan O'Brien, et al.
Leukemia
|
November 1, 1992
New drugs in the treatment of chronic lymphocytic leukemia
M J Keating, S O'Brien, L Robertson, et al.
Cancer Research
|
November 1, 1990
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia
R Grunewald, H Kantarjian, M J Keating, et al.
Page
of 129
Search research articles
Search
Showing results (411-420 of 1,289) with videos related to
Sort By:
Page
of 129
Leukemia
|
May 21, 2016
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes
F Cervantes-Gomez, V Kumar Patel, P Bose, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)
|
January 1, 1990
The effects of swabbing the skin on apparent blood ethanol concentration
G J Peek, A Marsh, J Keating, et al.
Leukemia & Lymphoma
|
June 20, 2015
Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells
Fabiola Cervantes-Gomez, Bethany Lavergne, Michael J Keating, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
March 1, 2007
Somatostatin decreases voltage-gated Ca2+ currents in GH3 cells through activation of somatostatin receptor 2
Seung-Kwon Yang, Helena C Parkington, Jacques Epelbaum, et al.
Journal of Biomedical Materials Research
|
January 15, 2000
Mechanical environment affects allograft incorporation
J Benevenia, M Zimmerman, J Keating, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 1995
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia
V Gandhi, E Estey, M Du, et al.
Endocrine
|
January 3, 2006
Ghrelin reduces voltage-gated potassium currents in GH3 cells via cyclic GMP pathways
Xue Feng Han, Yun Long Zhu, Maria Hernandez, et al.
Leukemia Research
|
August 4, 2009
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years
Stefan Faderl, William Wierda, Susan O'Brien, et al.
Leukemia
|
November 1, 1992
New drugs in the treatment of chronic lymphocytic leukemia
M J Keating, S O'Brien, L Robertson, et al.
Cancer Research
|
November 1, 1990
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia
R Grunewald, H Kantarjian, M J Keating, et al.
Page
of 129